巴塞罗那 - 全球医疗保健公司盖立复(MCE:GRF, MCE:GRF.P, NASDAQ:GRFS)宣布与生物医学高级研究和开发局(BARDA)合作，评估一种用于治疗芥子气导致眼部损伤的实验性眼药水。此次合作旨在探索目前正在开发用于干眼症(DED)的眼表免疫球蛋白(OSIG)眼药水，在中和这种化学战剂影响方面的潜力。 芥子气（俗称芥子气）会导致严重的眼部损伤，可能导致失明。临床前研究将重点关注O ...

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from ...

Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to ...

Grifols (GRFS) has established a partnership with the Biomedical Advanced Research and Development Authority to test investigational ocular ...

BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). If the preclinical evaluation is successful ...

以色列特拉维夫和美国北卡罗来纳州罗利 - 专业生物制药公司RedHill Biopharma Ltd. (NASDAQ: ...

The firm's QScout CBC diagnostic system is intended to deliver faster complete blood count test results and detect severe infection earlier.

MACH32 announced today that it has been awarded an EZ-BAA Advanced Research and Development contract from Biomedical Advanced ...

Synedgen has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop ...

First, the good news sa Netflix Philippines. No. 1 sa Top 10 Movies ngayong Oktubre 12, 2024, Sabado ang BarDa movie na That ...